Kanada - Kiingereza - Health Canada

teva canada limited - sotalol hydrochloride - tablet - 80mg - sotalol hydrochloride 80mg - beta-adrenergic blocking agents

Kanada - Kiingereza - Health Canada

teva canada limited - sotalol hydrochloride - tablet - 160mg - sotalol hydrochloride 160mg - beta-adrenergic blocking agents

Kanada - Kiingereza - Health Canada

pro doc limitee - sotalol hydrochloride - tablet - 80mg - sotalol hydrochloride 80mg - beta-adrenergic blocking agents

Kanada - Kiingereza - Health Canada

pro doc limitee - sotalol hydrochloride - tablet - 160mg - sotalol hydrochloride 160mg - beta-adrenergic blocking agents

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - sotalol hydrochloride - oral tablet - 80mg

Kanada - Kiingereza - Health Canada

sorres pharma inc - sotalol hydrochloride - tablet - 80mg - sotalol hydrochloride 80mg - beta-adrenergic blocking agents

Kanada - Kiingereza - Health Canada

sorres pharma inc - sotalol hydrochloride - tablet - 160mg - sotalol hydrochloride 160mg - beta-adrenergic blocking agents

Kanada - Kiingereza - Health Canada

sivem pharmaceuticals ulc - sotalol hydrochloride - tablet - 80mg - sotalol hydrochloride 80mg - beta-adrenergic blocking agents

Kanada - Kiingereza - Health Canada

sivem pharmaceuticals ulc - sotalol hydrochloride - tablet - 160mg - sotalol hydrochloride 160mg - beta-adrenergic blocking agents

Marekani - Kiingereza - NLM (National Library of Medicine)

bryant ranch prepack - sotalol hydrochloride (unii: hec37c70xx) (sotalol - unii:a6d97u294i) - oral sotalol hydrochloride is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. because of the proarrhythmic effects of sotalol (see warnings ), including a 1.5 to 2% rate of torsade de pointes or new vt/vf in patients with either nsvt or supraventricular arrhythmias, its use in patients with less severe arrhythmias, even if the patients are symptomatic, is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of sotalol treatment or increasing doses, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. the response to treatment should then be evaluated by a suitable method (e.g., pes or holter monitoring) prior to continuing the patient on chronic therapy. various approaches have been used to determine the response to antiarrhythmic therapy, includi